Democrats such as Elizabeth Warren had their eye on business and the working class during the first 2020 presidential primary debate in Miami.2020 Electionsread more
Huawei's legal chief told CNBC that the company makes "solutions for civil use."Technologyread more
The Chinese Ministry of Commerce maintained a firm stance against the U.S. during a weekly press conference on Thursday, less than two days ahead of a scheduled meeting...China Economyread more
The issue over health insurance marked the first stark divide among the candidates, and sparked a heated back-and-forth between many of the candidates on stage.Politicsread more
Four candidates mentioned China — but none of the Democratic contenders brought up trade in the debate.Politicsread more
The stock market is shrinking for several key reasons, but there's a way for investors to maneuver it, says Citi Research strategist Robert Buckland.Trading Nationread more
Credit Suisse initiated coverage of Tesla Wednesday with an "underperform" rating and a price target 15% below where the stock closed.Marketsread more
Something unusual is happening in financial markets, and it could mean more gains lie ahead for stocks, if history is any indication.Marketsread more
In a strategy to draw attention away from Wednesday's Democratic debate, President Donald Trump's reelection campaign bought out YouTube's "masthead," the leading...2020 Electionsread more
The Federal Aviation Administration said on Wednesday that is has found an issue with the Boeing 737 Max that the manufacturer must address before it lifts the grounding...Airlinesread more
The collapse of the deal potentially ended Sinclair's hopes of building a national conservative-leaning TV powerhouse that might have rivaled Fox News.Mediaread more
(Adds analyst comment, background, share movement)
May 28 (Reuters) - Mallinckrodt Plc said on Tuesday it would spin off its generic drugs business as a separate unit and keep constipation medicine Amitiza as part of its specialty branded drugs business, which will be renamed as Sonorant Therapeutics Plc.
The company had said in December it was open to a sale of the generics business or would spin it off in the second half of 2019. It had said Amitiza would be part of the spun-off unit.
Shares of Mallinckrodt were down 6.3% in noon trading, as concerns related to its Acthar gel continued to weigh on the stock.
Mallinckrodt shares have lost about 30% of their value since the drugmaker said last week it was suing U.S. health agencies over changes to how Medicaid rebates are calculated for its Acthar gel, which is used to treat multiple sclerosis and infantile spasms.
"Acthar remains front and center to the Mallinckrodt debate and we believe that investors may be viewing the move of Amitiza back to brands as management looking to offset potential negative impact from an Acthar CMS ruling," SVB Leerink analyst Ami Fadia said.
Amitiza drug brought in sales of $53 million in the first quarter, constituting nearly 22% of the drugmaker's generic drug unit sales.
The company said on Tuesday it believed the new generics company, which will be called Mallinckrodt Inc, would emerge with less debt than previously anticipated without the Amitiza drug. It also cited the generic unit's strong performance.
"While we understand this short-term protective move, this only aggravates the longer-term cliff for Specialty Brands with Ofirmev and Amitiza seeing generic entry by 2021," Stifel analyst Annabel Samimy said, referring to emerging competition for Amitiza and the company's injection to treat pain.
(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli and James Emmanuel)